Myocarditis following adeno-associated viral gene expression of human soluble TNF receptor (TNFRII-Fc) in baboon hearts

[1]  R. Herzog.  Immune responses to AAV capsid: are mice not humans after all? , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[2]  E. Bruckheimer,et al.  Long-term suppression of experimental arthritis following intramuscular administration of a pseudotyped AAV2/1-TNFR:Fc Vector. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[3]  T. Conlon,et al.  Recombinant Adeno-Associated Virus Serotype 9 Leads to Preferential Cardiac Transduction In Vivo , 2006, Circulation research.

[4]  J. Balschi,et al.  Interaction of insulin and AMPK in the ischemic heart: another chapter in the book of metabolic therapy? , 2006, Circulation research.

[5]  J. Rasko,et al.  Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response , 2006, Nature Medicine.

[6]  Lili Wang,et al.  Biology of AAV serotype vectors in liver-directed gene transfer to nonhuman primates. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[7]  Xiao Xiao,et al.  Sustained Whole-Body Functional Rescue in Congestive Heart Failure and Muscular Dystrophy Hamsters by Systemic Gene Transfer , 2005, Circulation.

[8]  R. Herzog,et al.  Systemic protein delivery by muscle-gene transfer is limited by a local immune response. , 2005, Blood.

[9]  M. Broder,et al.  Mechanisms of differential immunogenicity of tumor necrosis factor inhibitors , 2005, Current rheumatology reports.

[10]  D. Kem,et al.  Tumor Necrosis Factor α, Rapid Ventricular Tachyarrhythmias, and Infarct Size in Canine Models of Myocardial Infarction , 2005, Journal of cardiovascular pharmacology.

[11]  Simon C Watkins,et al.  Inhibition of tumor necrosis factor receptor-1-mediated pathways has beneficial effects in a murine model of postischemic remodeling. , 2004, American journal of physiology. Heart and circulatory physiology.

[12]  B. McGowan,et al.  Tumor Necrosis Factor Receptors 1 and 2 Differentially Regulate Survival, Cardiac Dysfunction, and Remodeling in Transgenic Mice With Tumor Necrosis Factor-&agr;–Induced Cardiomyopathy , 2004 .

[13]  J. McMurray,et al.  Targeted Anticytokine Therapy in Patients With Chronic Heart Failure: Results of the Randomized Etanercept Worldwide Evaluation (RENEWAL) , 2004, Circulation.

[14]  R. Robinson,et al.  Efficacy of anti-tumor necrosis factor therapy in the treatment of spontaneous endometriosis in baboons. , 2004, Fertility and sterility.

[15]  A. Gottlieb,et al.  Etanercept as monotherapy in patients with psoriasis. , 2003, The New England journal of medicine.

[16]  M. Braun,et al.  Case Reports of Heart Failure after Therapy with a Tumor Necrosis Factor Antagonist , 2003, Annals of Internal Medicine.

[17]  K. Tsuchida,et al.  In vivo gene transfer of soluble TNF‐α receptor 1 alleviates myocardial infarction , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[18]  R. Herzog,et al.  Influence of vector dose on factor IX-specific T and B cell responses in muscle-directed gene therapy. , 2002, Human gene therapy.

[19]  C. Ritchlin,et al.  Clinical, histological, and immunophenotypic characteristics of injection site reactions associated with etanercept: a recombinant tumor necrosis factor alpha receptor: Fc fusion protein. , 2001, Archives of dermatology.

[20]  O. Danos,et al.  Factors influencing cross‐presentation of non‐self antigens expressed from recombinant adeno‐associated virus vectors , 2001, The journal of gene medicine.

[21]  A. Nienhuis,et al.  Factors influencing in vivo transduction by recombinant adeno-associated viral vectors expressing the human factor IX cDNA. , 2001, Blood.

[22]  Y. Kan,et al.  Adeno-associated viral vector-mediated vascular endothelial growth factor gene transfer induces neovascular formation in ischemic heart. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[23]  P. Robbins,et al.  Soluble tumor necrosis factor receptor abrogates myocardial inflammation but not hypertrophy in cytokine-induced cardiomyopathy. , 2000, Circulation.

[24]  D. Wagner,et al.  The role of tumor necrosis factor in the pathophysiology of heart failure. , 2000, Journal of the American College of Cardiology.

[25]  James M. Wilson,et al.  Humoral Immunity to Adeno-Associated Virus Type 2 Vectors following Administration to Murine and Nonhuman Primate Muscle , 2000, Journal of Virology.

[26]  D. Simcoe,et al.  The Pharmacokinetics of Etanercept in Healthy Volunteers , 2000, The Annals of pharmacotherapy.

[27]  K. Propert,et al.  Immune responses to adenovirus and adeno-associated virus in humans , 1999, Gene Therapy.

[28]  J. Mehta,et al.  Kinetics of tumor necrosis factor α in plasma and the cardioprotective effect of a monoclonal antibody to tumor necrosis factor α in acute myocardial infarction , 1999 .

[29]  J. Mehta,et al.  Kinetics of tumor necrosis factor alpha in plasma and the cardioprotective effect of a monoclonal antibody to tumor necrosis factor alpha in acute myocardial infarction. , 1999, American heart journal.

[30]  R. Samulski,et al.  Production of High-Titer Recombinant Adeno-Associated Virus Vectors in the Absence of Helper Adenovirus , 1998, Journal of Virology.

[31]  A. Koretsky,et al.  Dilated Cardiomyopathy in Transgenic Mice With Cardiac-Specific Overexpression of Tumor Necrosis Factor-α , 1997 .

[32]  E. Tindall,et al.  Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. , 1997, The New England journal of medicine.

[33]  H. Oral,et al.  Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). , 1996, Journal of the American College of Cardiology.

[34]  A. Matsumori,et al.  Therapeutic Effect of Anti‐Tumor Necrosis Factor‐α Antibody on the Murine Model of Viral Myocarditis Induced by Encephalomyocarditis Virus , 1994, Circulation.

[35]  P. Allen,et al.  Neutralization of endogenous tumor necrosis factor ameliorates the severity of myosin-induced myocarditis. , 1992, Circulation research.